Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI Inc (PYNKF) delivers cutting-edge imaging solutions for cancer surgery, specializing in AI-enhanced optical coherence tomography (OCT) systems. This page provides official updates on regulatory milestones, clinical research, and technological advancements shaping surgical oncology.
Investors and medical professionals will discover timely updates about the company’s FDA-cleared S-Series OCT platform, B-Series AI integration progress, and strategic partnerships. Content includes earnings reports, trial outcomes, and educational initiatives demonstrating real-world clinical impact.
Key updates cover surgical margin visualization innovations, regulatory submissions, and peer-reviewed study results. All materials are sourced directly from company filings and verified medical publications to ensure accuracy.
Bookmark this page for consolidated access to Perimeter’s latest developments in AI-driven surgical imaging. Regularly updated to reflect new achievements in precision oncology and operational growth.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has successfully completed the technology transfer for manufacturing its S-Series Optical Coherence Tomography (OCT) imaging systems with Minnetronix Medical. This milestone allows Perimeter to scale up production efficiently and meet customer demands. The Perimeter S-Series OCT, cleared by the U.S. FDA, provides real-time margin visualization in surgical settings, potentially improving patient outcomes. The company is also advancing its ImgAssist AI technology, supported by a $7.4 million grant, and plans a pivotal study to evaluate its effectiveness in breast conservation surgery.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported 2020 financial results and significant milestones. Key achievements included FDA 510(k) clearance for the S-Series OCT, paving the way for U.S. market entry. The company received a $7.4 million grant from CPRIT for its ATLAS AI project and appointed new leadership to strengthen its board. Notable future initiatives include a multi-site clinical study to assess re-operation rates in breast conservation surgery. The recent Breakthrough Device Designation from the FDA underscores the potential of its innovative technologies in enhancing surgical outcomes.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced that CEO Jeremy Sobotta will present a company overview at the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 4:00 p.m. ET. The company focuses on transforming cancer surgery with advanced imaging tools. Its Optical Coherence Tomography (OCT) Imaging System offers real-time visualization of tissue margins, enhancing surgical outcomes. Perimeter is advancing the ImgAssist AI technology with a $7.4 million grant, aiming to improve breast cancer surgery results.
Perimeter Medical Imaging AI (OTC:PYNKF) announced a physician-led webinar on its Optical Coherence Tomography (OCT) Imaging System, following its FDA 510(k) clearance. The system aids real-time tissue imaging during surgeries, enhancing margin visualization. The webinar features prominent surgeons discussing OCT technology's impact on breast cancer surgeries and future AI applications. CEO Jeremy Sobotta emphasized the company's commitment to commercialization and improving patient outcomes through advanced imaging tools.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced a new clinical study led by Dr. Beth DuPree, aiming to enroll 100 patients at Northern Arizona Healthcare. The study will evaluate the efficacy of Perimeter’s Optical Coherence Tomography (OCT) Imaging System during breast-conserving surgeries. This follows successful results from a prior 20-patient study. The new trial seeks to validate the technology's potential to reduce reoperations by providing real-time tissue visualization, aiming for better outcomes and lower healthcare costs.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) will be presenting at the Lytham Partners Spring 2021 Investor Conference on March 30, 2021, at 2:45 p.m. ET. CEO Jeremy Sobotta will provide a company overview highlighting their advanced imaging tools aimed at improving cancer surgery outcomes. The webcast can be accessed on the company's website, with an archived replay available after the event. Management will also engage in virtual one-on-one meetings during the conference, running from March 30 to April 1, 2021.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) has successfully accelerated the expiry of certain share purchase warrants, raising approximately $8.3 million from the exercise of about 4.3 million warrants. This included 3,412,196 warrants exercised after February 1, 2021, yielding $6.8 million in cash. The funds will support the commercialization of their OCT Imaging system, recently cleared for U.S. market entry. CEO Jeremy Sobotta highlighted the importance of this support, which enhances the company's development efforts in addressing unmet surgical needs.
Perimeter Medical Imaging AI, Inc. has received 510(k) clearance from the U.S. FDA for its Optical Coherence Tomography (OCT) Imaging System (v2.1). This system is designed to provide cross-sectional, real-time visualization of tissue microstructures during surgical procedures, addressing significant unmet medical needs. CEO Jeremy Sobotta highlighted the system's potential to improve patient outcomes and streamline surgical workflows. The clearance marks a pivotal step for Perimeter in bringing its 'commercial ready' product to the U.S. market, alongside future enhancements under the ATLAS AI project.
Perimeter Medical Imaging AI, Inc. (PINK.V, PYNKF) reported a significant update regarding the exercise of share purchase warrants. As of February 25, 2021, approximately 3.1 million of the 3.5 million warrants have been exercised, raising $7.3 million, which supports the company's commercialization plans for its advanced imaging tools. The exercise price is set at $2.00 per share, and the remaining warrants could provide an additional $682,128 in proceeds if exercised by the accelerated expiry date of March 8, 2021.
Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) announced participation in two upcoming virtual investor conferences. Jeremy Sobotta, CEO, will present at the TSX Life Science Investor Day on February 25, 2021, at 11 am ET, and at the HC Wainwright Global Lifesciences Conference on March 9, 2021, starting at 7 am ET. Perimeter develops advanced imaging tools for cancer surgery, aiming to improve patient outcomes and reduce healthcare costs. Their OTIS™ platform allows for real-time, high-resolution imaging of excised tissue, enhancing surgical decision-making.
